{"organizations": [], "uuid": "13566136587ce6f2c235b5a03371838a651725d5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/06/globe-newswire-bellicum-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call-and-webcast.html", "country": "US", "domain_rank": 767, "title": "Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-06T15:00:00.000+02:00", "replies_count": 0, "uuid": "13566136587ce6f2c235b5a03371838a651725d5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/06/globe-newswire-bellicum-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call-and-webcast.html", "ord_in_thread": 0, "title": "Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "houston", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "bellicum pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "bellicum pharmaceuticals", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "HOUSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday, March 13, 2018 at 5:00 p.m. Eastern to report its fourth quarter and full year 2017 financial results and provide a corporate update.\nTo access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com . An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website for at least two weeks following the call.\nAbout Bellicum Pharmaceuticals\nBellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com .\nInvestors:\nBellicum Pharmaceuticals, Inc.\nAlan Musso, CFO\n832-384-1116\namusso@bellicum.com\nMedia:\nBMC Communications\nBrad Miles\n646-513-3125\nbmiles@bmccommunications.com\nSource: Bellicum Pharmaceuticals\nSource:Bellicum Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=HXS_prldpUWd_zRXjUhNor3Ww8ugjaEBfCEyG7LvV9NFtWu1YOsGx6oaR0SFpwmQCPPn9J9nQ3IkSDpHQ9q8dxre1tYcMfov7FoVuv9I8QKnqKhlRAdkDPaFWCNhk5X4MVPifwEYsMUBwkUCHUJBwtw2TbxcEdM4iR21J8Wv4MEAbZLs7wysR9GowkvvNSZpgde1SawYuNHJ_6-EDvuCfmMQ62S9Q_4Lb34WizZF7cDJaAL7NQ6xN-wIqC2eRcy5keqASBiLa8y-OLQnQiAJTSSqMisoolPvpJpBvuLGMJg=", "https://www.globenewswire.com/Tracker?data=pg8oes1vKgojDUZVdQLb-t6xs_dk-aDcLKFrp8KrZiEaHRKwWzgWb8tJMW46kllwnxsoPfIrz5ICgmdNvUjxZw==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/367763ec-20f1-4adf-8ddb-a01e966e31e3", "https://www.globenewswire.com/Tracker?data=QMbCix-8dmeJXwMxzkir7bxOF8biPzGTT10HWXvTo6Jbct-vSCAzO3km1CWWUo57Jgcvv7UAxki9MjTX8IximfnAheDgvPtDFxsBZ0DyfgM=", "https://www.globenewswire.com/Tracker?data=_QuXt0dmCRRXeLasmxeAs29tfOH9_2kG5-eZZWrZzsiuFwEC_ploXxqTgRaBgHeZjhLoe4ZKZBWuhhJFu3IiQbKMbxS_kPnp_DRgYc5auPXUVUCXp2j0WOGLpiDsb-pNGfebIOKa9RRm9M1RqXKA4g==", "https://www.globenewswire.com/Tracker?data=JhRZ1bR0sL-LWQ5yAA8eaVznAkhfVeFA7PCd_Z3N-W8cKqhU36u4pPWlCOoOhmGVUcpn997lJ6cw78sMInzvoElClrmcmNho0kk5PpIdQk5_LPdthzNfcgNYdu53o43ugqBtIfODdcKumuNO3nyHVQPG9TPB2vrn1soYqQ4XfMroYyketWdfiCyXL4YTT5pdo7gXUD7Wetg932iZX_4XlhQsmLi_R4sawzEJLxyvLT26fvXsweg3LG-gUm1bUIob6ZLz1nyrYmH39Q0irPw91B1G3E1Ym4Hpa9AAvNN1Hx36uSH19wMbcbhMAdhnTqYwG2Dh9x6cVNyYZClcbA9aq0timgb2SA6Jy-j_NfAKsVl88FvFVpLTVfsdAGvY4-1tlbEe8d1y1ZEnZAuOjnvNTQWI5x_fACWseBuBC2foVNSYqPI2Z4xEm5o_21pG82h1ZQSlrWjEXfzoR3v9C0_rOCK__4L8-CAnFF5vk1p", "https://www.globenewswire.com/Tracker?data=OGzXQ7yjcT78PudEwFTg-wkx2oIO9Wx24tfwjsqyWkDgrsCzZBN_t-MmO1kMxZvdC2kCZswO1kElYmlkuAATb4-dKh2rFZbsi8JWeokjGWhcbEW63H1SZtrCMJzkkhYOPgakfDBjh_JqsiwepSxUDCeuXeLpBwRq-VDRjflCAk54YZEn7gcOJM27VYJpgNqzu3l6YtMee_kh-STd3QmyY4QnhxJzVT4sybZgqYuDpTec65yVuKRCdx62tTtpZmuA"], "published": "2018-03-06T15:00:00.000+02:00", "crawled": "2018-03-06T15:50:05.005+02:00", "highlightTitle": ""}